Assay for inhibition of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp)

CS Carolina Q Sacramento
NF Natalia Fintelman-Rodrigues
JT Jairo R Temerozo
AS Aline de Paula Dias Da Silva
SD Suelen da Silva Gomes Dias
CS Carine dos Santos da Silva
AF André C Ferreira
MM Mayara Mattos
CP Camila R R Pão
CF Caroline S de Freitas
VS Vinicius Cardoso Soares
LH Lucas Villas Bôas Hoelz
TF Tácio Vinício Amorim Fernandes
FB Frederico Silva Castelo Branco
MB Mônica Macedo Bastos
NB Núbia Boechat
FS Felipe B Saraiva
MF Marcelo Alves Ferreira
SJ Steffen Jockusch
XW Xuanting Wang
CT Chuanjuan Tao
MC Minchen Chien
WX Wei Xie
DP Dinshaw Patel
AG Aitor Garzia
TT Thomas Tuschl
JR James J Russo
RR Rajith K R Rajoli
CP Carolina S G Pedrosa
GV Gabriela Vitória
LS Letícia R Q Souza
LG Livia Goto-Silva
MG Marilia Zaluar Guimarães
SR Stevens K Rehen
AO Andrew Owen
FB Fernando A Bozza
DB Dumith Chequer Bou-Habib
JJ Jingyue Ju
PB Patrícia T Bozza
TS Thiago Moreno L Souza
ask Ask a question
Favorite

The pre-assembled SARS-CoV-2 RdRp complex (nsp12/nsp7/nsp8)24,25 was incubated with appropriate concentrations of aqueous daclatasvir dihydrochloride for 15 min at room temperature in reaction buffer. Then the annealed RNA template-loop-primer in reaction buffer was added to the RdRp-daclatasvir mixture and incubated for an additional 10 min at room temperature. Finally, UTP or sofosbuvir-TP was added and incubation was carried out for 1 h at 30°C. The final concentrations of the reagents in the 20 μL extension reactions were 1 μM RdRp complex (nsp12/nsp7/nsp8), 500 nM RNA template-loop-primer, 0, 1, 4, 16 or 64 μM daclatasvir and 3 μM UTP or 15 μM sofosbuvir-TP. Following desalting, the samples were subjected to MALDI-TOF MS analysis.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A